Adicet Bio Inc
Research Adicet Bio Inc (1IJ) on Bullrun: market cap EUR 72.08M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker1IJ
- ExchangeF
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 72.08M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 20.24M
- Free cash flow-USD 21.53M
Valuation Snapshot
latest market cap is EUR 72.08M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 116.80M | -USD 96.98M | n/a | -17.98 | USD 38.92M | USD 14.74M | USD 159.21M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-28 | EUR 72.08M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Adicet Bio Inc
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Adicet Bio Inc's market cap?
Adicet Bio Inc's market capitalization is EUR 72.08M.
What does Adicet Bio Inc do?
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.